Angel Arnaout, MD, MSc, FRCSC, FACS, MBA

Associate Professor, University of Ottawa
Associate Scientist, Ottawa Hospital Research Institute
Breast Surgical Oncologist
Ottawa Hospital
Ottawa, ON

Dr. Arnaout is a Breast Surgical Oncologist at the Ottawa Hospital, Associate Professor at the University of Ottawa Department of Surgery and Associate Scientist at the Ottawa Hospital Research Institute. She is a member of the Oncoplastic Partnership Group and Workshop Series. Her passion is to scale up Oncoplastic breast  surgery across Canada.

Philippe Bedard, MD, FRCPC

Associate Professor of Medicine
University of Toronto
Staff Medical Oncologist, Dept of Oncology
Princess Margaret Cancer Centre
Toronto, ON

Dr. Bedard received his medical degree from the University of Toronto where he was awarded the Cody Academic Silver Medal. He completed his Internal Medicine and Medical Oncology specialty training at the University of Toronto. He received additional fellowship training in clinical and translational breast cancer research at the Breast International Group (BIG).

In recognition of his research excellence, Dr. Bedard received the 2012 Career Development Award from the the Conquer Cancer Foundation of the American Society of Clinical Oncology.

Vanessa Bernstein, BA, MSc, MD, FRCPC

Clinical Associate Professor of Medicine
University of British Columbia,
Medical Oncologist
BC Cancer Agency, Vancouver Island Centre
Victoria, BC

Dr. Vanessa Bernstein is a medical oncologist at the Vancouver Island Cancer Centre who specializes in breast cancer and melanoma. She graduated magnum cum laude with a Bachelor of Arts from Dartmouth College, New Hampshire.  She completed her MD, Internal Medicine and Medical Oncology training at the University of British Columbia.  She was the 2000 Canadian Breast Cancer Foundation BC/Yukon Chapter Research Fellow. She used this opportunity to complete a Master’s of Science in Clinical Epidemiology from the Harvard School of Public Health.

Dr. Bernstein is the medical director of the Systemic Therapy Clinical Trials Unit at the Vancouver Island Cancer Centre. She has been a local and provincial principal investigator for many phase I, II and III clinical trials. She chaired the BC Cancer Agency Breast Cancer Systemic Policy Group from 2013-2015.

She is a Clinical Associate Professor of Medicine at the University of British Columbia and has taught many medical students and residents.

Muriel Brackstone, MD, PhD, FRCSC

Surgical Oncologist, London Regional Cancer Program
Medical Director, London Breast Care Clinic
Director, London Tumour Biobank
Assoc. Professor,  Surgery & Oncology, Western University
London, ON

Dr. Muriel Brackstone is a breast surgical oncologist in London Ontario, and Medical Director of the London Breast Care Program. She is an Associate Professor of Surgery & Oncology at Western University and founding Medical Director of the London Tumour Biobank. She obtained her PhD in Clinical Trials through the Department of Pathology. Her clinical and research interests include translational and window of opportunity clinical trials for personalized preoperative treatment of breast cancer and for optimizing immuno-oncology research and treatment. Dr. Brackstone is a member of the Oncoplastic Partnership Group and Workshop Series. 

Christine Brezden-Masley, MD, FRCPC, PhD, MSc, BSc

Associate Professor of Medicine
University of Toronto
Toronto, ON

Bio will be added shortly

Stephen K. L. Chia, MD, FRCPC

Medical Oncologist,
BCCA, Vancouver Clinic
Associate Professor of Medicine,
Department of Medicine,
University of British Columbia,
Chair British Columbia Breast Tumour Group
Vancouver, BC

Stephen K. Chia, M.D., F.R.C.P. (Canada) is an Associate Professor of Medicine, Department of Medicine at the University of British Columbia, Vancouver, Canada.  He also is a staff oncologist with the British Columbia Cancer Agency (BCCA), Vancouver, Canada.  In addition, Dr. Chia serves as Chair for the British Columbia Breast Tumour Group and is physician coordinator for both the breast cancer and head and neck cancer clinical trials at the BCCA – Vancouver Cancer Centre.  He currently sits on the NCIC Clinical Trials Committee Executive, NCIC CTG Breast Executive, NCIC CTG Breast Correlative Science Committee, as well as being a member of the ASCO Scientific Committee (2009-2012). He was a Breast Track chair (Triple Negative/Cytotoxic/Local) for the ASCO 2011 Annual Meeting. He is an active researcher in phase I-III trials in breast cancer, head and neck cancer and investigational new drugs. He has a real interest in neoadjuvant systemic therapy for breast cancer and drug development, as well as the field of translation research of predictive biomarkers/assays.

Dr. Chia has been widely published (over 70 peer reviewed publications) in international peer-reviewed journals including New England Journal of MedicineJournal of Clinical Oncology, Lancet, Journal of the National Cancer Institute, Cell, Annals of Oncology and Clinical Cancer Research.  Recently he has written the Commentaries in the Lancet and Lancet Oncology for the latest EBCTCG Overview (2011), NOAH study (2010) and the GEPARQUINTTO study (2012) respectively. An active researcher, he is currently carrying out clinical and translational studies in breast cancer with peer reviewed grant funded research from the National Cancer Institute of Canada, National Institute of Health (USA), Canadian Breast Cancer Research Alliance and Canadian Breast Cancer Foundation – British Columbia/Yukon Chapter.

He received his bachelor’s degree in Pharmacology from the University of British Columbia, where he also earned his medical degree in 1993.  He obtained his Internal Medicine Fellowship and Medical Oncology Fellowship also from the University of British Columbia. Dr. Chia then completed post-fellowship training from 1999-2000 with the Dept. of Advanced Therapeutics – British Cancer Research Centre and at the Institute of Molecular Medicine with the University of Oxford.

Debjani Grenier MD, FRCPC

Medical Oncologist, CancerCare Manitoba
University of Manitoba
Winnipeg, MB

Dr. Grenier is a medical oncologist and a clinical investigator at CancerCare Manitoba and she holds academic appointments in the Department of Medicine, Section of Medical Oncology and Hematology at the University of Manitoba. Her main areas of interest are breast and skin cancers and she was the past Chair of the CancerCare Manitoba Breast Cancer Disease Site Group.

Dr. Grenier was the Program Director for the Medical Oncology Training Program at the University of Manitoba up until July 2016 and the previous Chair of the Medical Oncology Examination Board of the Royal College of Physicians and Surgeons of Canada. She is a member of the Medical Oncology Specialty Committee of the Royal College and has been actively involved in the development and implementation of the Competency Based Education Curriculum for Canadian Medical Oncology Training Programs.

Her research interests include identifying and characterizing cardiotoxicity of cancer therapies and risk factors for breast cancer. She is also involved in determining ways of effectively communicating with cancer patients by means of decision aids and audiotapes. She has been the site principal investigator of multiple phase III breast cancer trials and the local representative for national and international clinical trial co-operative groups, including CCTG and the NRG. She is the current Co-chair of the Locally Advanced Breast Cancer Canadian National Consensus group, and has a research interest in the area of neoadjuvant therapy for breast cancer.

 Anil Abraham Joy, MD, FRCPC

Professor, Department of Oncology
Division of Medical Oncology
University of Alberta,
Edmonton, AB

Dr. Anil Abraham Joy is a Professor in the Department of Oncology, Division of Medical Oncology in the Faculty of Medicine and Dentistry at the University of Alberta and a staff staff medical oncologist at the Cross Cancer Institute in Edmonton, Alberta. In addition to his other appointments, he has previously served as Chair for the Northern Alberta Breast Cancer Program and the Provincial Chair for the Alberta Breast Cancer Program. He currently serves as a member of the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) where they assess the clinical evidence and cost-effectiveness of cancer drugs in order to make recommendations to the provinces and territories to help guide their drug funding decisions. His primary oncologic clinical and research areas of interest include breast and thoracic malignancies. He has interest in medical education, Phase II/III clinical and translational research in breast and thoracic malignancies, cardio-oncology-exercise research, clinical guideline development, and global oncology/regional disparity issues.

Renee Hanrahan, MD, FRCSC

Oncologic and Reconstructive Breast Surgeon
General Surgeon
Royal Victoria Regional Hospital and Simcoe Muskoka Regional Cancer Centre, Barrie
Chief of General Surgery
Royal Victoria Hospital, Barrie
Barrie, ON

Bio to be posted shortly

Marianna Kapala MD, FRCSC

Lecturer, University of Toronto
Breast Surgeon, Trillium Health Partners
Medical Director, Breast Diagnostic Assessment Program
Betty Wallace Women’s Health Centre
Toronto, ON

Dr. Kapala is a General and Breast Surgeon at Trillium Health Partners,  a University of Toronto affiliated community hospital. She is the Medical Director of the  Breast Diagnostic Assessment Program at the Betty Wallace Women’s Health Center and a Lecturer at the  University of Toronto. She is an Investigator of the Institute for Better Health and a member of the Canadian Oncoplastic Partnership Group and Workshop Series.

Wendy Lam, BSc. (Pharm), MD, FRCPC

Hematologist and Medical Oncologist
Burnaby Hospital Regional Cancer Center
Director, BC Community Oncology Trialists
Burnaby, BC

Dr. Wendy Lam is a hematologist and medical oncologist at the Burnaby Hospital Regional Cancer Centre.

She received her B.Sc (Pharmacy) at Dalhousie University and her MD from University of British Columbia. She then completed her Internal Medicine residency at UBC and Hematology fellowship at McMaster University.

She is the Founding Director of the British Columbia Community Oncology Trialists (BC Cot), which is a collaborative group of oncologists and hematologists involved in clinical research.

Her other interests include education of patients through meeting with patient groups. She has also been instrumental in organizing meetings for continued medical education.

She is Director of the Society of Hematology and Oncology of BC at British Columbia Medical Association

Heather L. McArthur, MD, MPH

Medical Director, Breast Oncology
Samuel Oschin Comprehensive Cancer Institute
Associate Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, CA

Heather McArthur, MD, MPH is Medical Director of Breast Oncology at Cedars-Sinai Medical Center (CSMC). Dr. McArthur is a medical oncologist with a clinical practice dedicated to the care of patients with breast cancer. Her research activities are focused on innovations in the diagnosis and treatment of breast cancer, with a particular interest in novel immune therapy strategies. For example, she is currently evaluating the impact of tumor destruction with freezing (cryoablation) or radiation in combination with immune stimulation for the treatment of women with early stage breast cancer. It is hoped that by augmenting one’s immune response to the unique biologic features of one’s tumor, that an affected individual may develop long-term immunity against their tumor, and thus, be cured.

Dr. McArthur completed formal medical oncology training in Canada where she was awarded a highly competitive grant that funded an advanced fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. Thereafter, she joined MSKCC as faculty where she developed the institutional breast cancer immunotherapy program before joining CSMC in 2016. She has a Master’s in Public Health with a focus on clinical trial design from Harvard University and has mentored many medical students, residents, fellows, and junior faculty in the conduct and reporting of several studies – two of which directly informed national (NCCN) treatment guidelines.

Dr. McArthur has held several leadership positions in the field including Co-Chair of a Breast International Group Immunotherapy Taskforce, member of a NCI Breast Cancer Immuno-Oncology (IO) Working Group, member of a NCI Breast Cancer IO Task Force, and member of an Alliance for Clinical Trials in Oncology IO Committee. She has served ASCO on the Annual Meeting IO Scientific Committee, the YIA/CDA Grant Selection Committee, the Breast Cancer Symposium Program Committee, the Annual Meeting Grant Writing Workshop, a Guideline Expert Panel, and Educational Book Expert Panels. She has participated in the ASCO Leadership Development Program; reviewed manuscripts for various high impact journals; authored numerous articles; and served on many study steering committees. She has designed, conducted, and reported on many studies in breast cancer and is currently the co-PI for a large, randomized, international phase 3 study exploring adjuvant chemotherapy with or without immune therapy for the treatment of triple negative breast cancer (IMpassion030).

Elaine McKevitt, BSc, MED, MD, FRCS(C), FACS

Clinical Associate Professor, University of British Columbia
Vancouver, BC

Dr. McKevitt is a Breast and General Surgeon at Providence Health Care in Vancouver. She did her medical training and General Surgery residency in British Columbia. She also holds a Masters degree in Education, UBC. Her clinical practice is focused at Mount Saint Joseph Hospital, Vancouver, where she is also active in teaching, breast cancer research, and multidisciplinary rounds at the Providence Breast Center.

Dr. McKevitt is the chair of the BC Cancer Surgeon Network Breast Surgical Tumour Group. Through the surgical tumor group Dr. McKevitt has led the Breast Cancer Synoptic Operative Report initiative, led the updating of BC Cancer surgical cancer management guidelines, and was guest co-editor of the 2018 BCMJ theme edition on breast cancer. She has been involved in the development of National Standards for Breast Cancer Surgery through the Canadian Partnership Against Cancer.

Jeannie Richardson, MD, FRCSC

Lead, General Surgery, Trillium Health Partners
Mississauga Hospital and Queensway Health Centre
Lecturer, Department of Surgery
Faculty of Medicine, University of Toronto
Toronto, ON

Dr. Jeannie Richardson is a Community General Surgeon at Trillium Health Partners in Toronto, Ontario. She received her MD from Queen’s University and completed her residency training in Toronto. In 2016 she co-founded the Canadian Oncoplastic Partnership Group and is the Director of the Oncoplastic Partnership Workshop. The workshop is the only hands-on Oncoplastic course in Canada and has successfully taught Oncoplastic Surgery to over 200 surgeons over the last 3 years. Her clinical interests include Oncoplastic Surgery, mesh-free hernia repair and complex abdominal wall hernias. Dr. Richardson is a Lecturer at the University of Toronto.

Josée-Anne Roy,  MD

Medical Oncologist, Hematologist
Université de Montréal
Montréal, QC

Clinical research studies in breast cancer and CCTG as Principal investigator and sub investigator in clinical studies in Colon, Lung, Pancreatic and hematological cancers.

Christine Simmons, MD, MSc, FRCPC

Medical Oncologist,
British Columbia Cancer Agency,
Vancouver, BC

Dr. Christine Simmons is a Medical Oncologist at the BCCA Vancouver.  She completed her residency training in Toronto, and completed a fellowship in Locally Advanced Breast Cancer at Princess Margaret Hospital in Toronto.  She also completed a Master’s in Clinical Epidemiology at University of Toronto.  She is a Clinical Assistant Professor at the University of British Columbia in the Faculty of Medicine.  She is past Chair of the Locally Advanced Breast Cancer Canadian National Consensus group, and has a strong research interest in the area of neoadjuvant therapy for breast cancer.  In July 2014 she took on the role of Clinical Skills Course Director in the undergraduate medical program at UBC.